-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Otjg4URVCXv2xUXfDabByPbrMfOMgF+Fk6rhY405oazSG7q8ouDRmFRNI5xGknbg n0mRcANP9w1b0qTiCY4O+A== 0001144204-08-018624.txt : 20080331 0001144204-08-018624.hdr.sgml : 20080331 20080331084659 ACCESSION NUMBER: 0001144204-08-018624 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20071231 FILED AS OF DATE: 20080331 DATE AS OF CHANGE: 20080331 EFFECTIVENESS DATE: 20080331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADVANCED PLANT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000943535 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 592762023 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30256 FILM NUMBER: 08721663 BUSINESS ADDRESS: STREET 1: 43 W 33RD STREET CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 2124027878 MAIL ADDRESS: STREET 1: 43 W 33RD STREET CITY: NEW YORK STATE: NY ZIP: 10001 NT 10-K 1 v108685_nt10k.htm
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
 

FORM 12b-25
 
 
NOTIFICATION OF LATE FILING
SEC. FILE NUMBER
000-30256
Check One): x Form 10-K and Form 10-KSB ࿠ Form 20-F࿠ Form 11-K࿠
࿠ Form 10-Q and Form 10-QSB ࿠ Form N-SAR
CUSIP NUMBER
00756F201
 
For Period Ended: December 31, 2007
 
 
࿠ Transition Report on Form 10-K
 
 
࿠ Transition Report on Form 20-F
 
 
࿠ Transition Report on Form 11-K
 
 
࿠ Transition Report on Form 10-Q
 
 
࿠ Transition Report on Form N-SAR
 
 
For the Transition Period Ended:
 
 
 
 
 
 
 
 
 
 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 
PART I - REGISTRANT INFORMATION
 
Advanced Plant Pharmaceuticals, Inc.
Full Name of Registrant
not applicable
Former Name if Applicable
43 West 33rd Street
Address of Principal Executive Office(Street and Number)
New York, New York 10001
City, State and Zip Code

PART 11 - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).
 
x
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
࿠
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 
 
 

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K and 10-KSB, 20-F, 11-K, 10-Q and 10-QSB, N-SAR, or the transition report on portion thereof, could not be filed within the prescribed time period.

The Registrant's Form 10-KSB for the year ended December 31, 2007 could not be filed within the prescribed time period because the Registrant has not been able to review certain information and data relating to and necessary for the accurate completion of the Registrant's financial statements. The Registrant anticipates that the Form 10-KSB Annual Report, will be filed on or before the 15th calendar day following the prescribed due date of the Registrant's Form 10-KSB.
 
PART IV - OTHER INFORMATION
 
(1)
 
Name and telephone number of person to contact in regard to this notification
 
 
David Lieberman
(Name)
(212)695-3334
(Area Code and Telephone Number)
 
 
(2)
 
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
 
 
 
x Yes ࿠ No
 
(3)
 
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 
 
 
࿠ Yes x No
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made
 
 
  
 
 

Advanced Plant Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: March 31, 2008
 
By: /s/David Lieberman
David Lieberman, CEO
 
 -----END PRIVACY-ENHANCED MESSAGE-----